at-001
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2016 (NCT03062384)
Timeline
Indications
Mechanism of action
- Aldose reductaseINHIBITOR
AKR1B1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04365699 | Phase 2 | Apr 8, 2020 | New York University |
| NCT04083339 | Phase 3 | Sep 30, 2019 | Applied Therapeutics, Inc., Harvard University |
| NCT03062384 | N/A | May 1, 2016 | Alltech Life Sciences Inc., University of Kentucky |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alltech Life Sciences Inc. | For profit | 1 | 0 | 1 | 2016 |
| Applied Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2019 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Kentucky | Academic/Hospital | 1 | 1 | 1 | 2016 |
5 organizations
Page 1 / 1